Outcomes of Laser Retinopexy for Retinal Tears in Pseudophakic Eyes with Multifocal Versus Monofocal Intraocular Lenses: A Matched Cohort Study

Abstract

Purpose

Performing laser retinopexy through multifocal intraocular lenses may be challenging due to aberrations of the peripheral retinal view. This study investigated the influence of multifocal versus monofocal intraocular lenses on outcomes of laser retinopexy for retinal tears.

Methods

Pseudophakic eyes (multifocal and monofocal intraocular lenses) that underwent in-office laser retinopexy for retinal tears, with a minimum follow-up of 3 months, were retrospectively analyzed. Eyes with multifocal intraocular lenses were matched to controls with monofocal intraocular lenses in a 1:2 ratio for age, gender, number, and location of retinal tears. The main outcome measure was the rate of complications.

Results

We included 168 eyes in the study. Fifty-six eyes (51 patients) with multifocal intraocular lenses were matched with 112 eyes (112 patients) with monofocal intraocular lenses. The mean follow-up was 26 months. Baseline characteristics were similar between two groups. No significant differences were noted in the rate of successful laser retinopexy without additional procedures (91% vs. 86% at 3 months and 79% vs. 74% during follow-up, in the multifocal intraocular lens and monofocal intraocular lens group, respectively). No significant differences were observed in the rate of subsequent rhegmatogenous retinal detachment (multifocal, 4% vs. monofocal, 6%, p=.716) or need for additional laser retinopexy for new tears (14% vs. 15%; p=.939). The surgery rates for vitreous hemorrhage (0% vs. 3%; p=.537), epiretinal membrane (2% vs. 2%; p=.553), and vitreous floaters (5% vs. 2%, p=.422) were not significantly different. Visual outcomes were also similar.

Conclusion

Multifocal intraocular lenses did not appear to negatively impact the outcomes of in-office laser retinopexy for retinal tears.

Keywords:

• Multifocal intraocular lens
• laser retinopexy
• pseudophakia
• retinal detachment
• retinal tears

Acknowledgements

Meeting presentation: This study was presented at an American Academy of Ophthalmology Annual Meeting in 2022.

Disclosure statement

Consultant for Alcon (YY), Bausch & Lomb (YY), Pykus (YY), Regeneron (YY), Tarsus (YY), Versant Health (YY), Allergan (MAK), Alimera (MAK), Genentech (MAK), and RegenexBio (MAK). Speaker for Genentech (MAK) and Regeneron (MAK).

Data availability statement

The data that support the findings of this study are available from the corresponding author [YY], upon reasonable request.

Additional information

Funding

None.